Agomab Therapeutics (AGMB) Total Non-Current Liabilities (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Total Non-Current Liabilities of $4.9 million for Q4 2025, down 49.83% year-over-year from $9.8 million in Q4 2024, and down 49.83% quarter-over-quarter from $9.8 million in Q4 2024.
Agomab Therapeutics (AGMB) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $4.9 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 49.83% year-over-year to $4.9 million; the TTM figure through Dec 2025 stood at $4.9 million (down 49.83% YoY), while the FY2025 annual figure was $4.9 million, down 50.46% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $4.9 million, down from $9.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $9.8 million in Q4 2024, with the low at $4.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 9.32 Bn |
| 10 | Agomab Therapeutics | 7.25 Mn | -250.33 Mn | - | 6.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.91 Mn |
| Dec 31, 2024 | 9.78 Mn |